3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Suspended
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
13
Pancreatic Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Sarcoma, Ewing
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Diseases
1
Prostate Cancer Metastatic
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Neoplasms
1
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1
Kidney Neoplasms
1
Hepatoblastoma
1
Fanconi Anemia, Complementation Group D1
1
Carcinoma, Transitional Cell
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma
1
Interventions
talazoparib
1
radium Ra 223 dichloride
1
olaparib
1
Pluvicto
1
Lutetium-177
1
Lutetium
1
CX 5461
1
BAY 2315497
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Castration Resistant Prostate Cancer (mCRPC)
×
talazoparib
×
Genitourinary
×
Clear all
NCT05425862
2023-12-11
REPAIR
Peter MacCallum Cancer Centre, Australia
Phase 1
Suspended
48 enrolled